Show simple item record

dc.contributor.authorKrah, Simon
dc.contributor.authorSchröter, Christian
dc.contributor.authorZielonka, Stefan
dc.contributor.authorEmpting, Martin
dc.contributor.authorValldorf, Bernhard
dc.contributor.authorKolmar, Harald
dc.date.accessioned2016-04-04T14:22:16Zen
dc.date.available2016-04-04T14:22:16Zen
dc.date.issued2016-02en
dc.identifier.citationSingle-domain antibodies for biomedical applications. 2016, 38 (1):21-8 Immunopharmacol Immunotoxicolen
dc.identifier.issn1532-2513en
dc.identifier.pmid26551147en
dc.identifier.doi10.3109/08923973.2015.1102934en
dc.identifier.urihttp://hdl.handle.net/10033/604382en
dc.description.abstractSingle-domain antibodies are the smallest antigen-binding units of antibodies, consisting either only of one variable domain or one engineered constant domain that solely facilitates target binding. This class of antibody derivatives comprises naturally occurring variable domains derived from camelids and sharks as well as engineered human variable or constant antibody domains of the heavy or light chain. Because of their high affinity and specificity as well as stability, small size and benefit of multiple re-formatting opportunities, those molecules emerged as promising candidates for biomedical applications and some of these entities have already proven to be successful in clinical development.
dc.language.isoenen
dc.titleSingle-domain antibodies for biomedical applications.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany.en
dc.identifier.journalImmunopharmacology and immunotoxicologyen
refterms.dateFOA2017-01-05T00:00:00Z
html.description.abstractSingle-domain antibodies are the smallest antigen-binding units of antibodies, consisting either only of one variable domain or one engineered constant domain that solely facilitates target binding. This class of antibody derivatives comprises naturally occurring variable domains derived from camelids and sharks as well as engineered human variable or constant antibody domains of the heavy or light chain. Because of their high affinity and specificity as well as stability, small size and benefit of multiple re-formatting opportunities, those molecules emerged as promising candidates for biomedical applications and some of these entities have already proven to be successful in clinical development.


Files in this item

Thumbnail
Name:
Krah et al.pdf
Size:
615.9Kb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record